Repare Therapeutics price target lowered to $10 from $25 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Repare Therapeutics (RPTX) to $10 from $25 and keeps a Buy rating on the shares. The analyst now only forecasts revenue for camonsertib in combination with lunresertib. Earlier this week, Repare announced that Roche (RHBBY) has decided to terminate its worldwide license and collaboration agreement for camonsertib following a review of its pipeline and evolving external factors, the analyst tells investors in a research note.